Skip to main content
Home > Week in Review > Clinical Status

Chronological Index of : Clinical Status

 Current Issue
  • DPX-RSV: Phase I started

    Immunovaccine Inc. (TSX:IMV; OTCQX:IMMVF), Halifax, Nova Scotia Product: DPX-RSV Business: Infectious Molecular target: NA Description: Vaccine containing respiratory syncytial virus (RSV) SHe antigen and formulated …

    Published on 8/24/2015
  • Interferon beta: Phase IIa started

    Synairgen plc (LSE:SNG), Southampton, U.K. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Interferon beta (IFNB) (AZD9412, SNG001) (formerly SNG-1) Business: Inflammation Molecular target: Type I interferon…

    Published on 8/24/2015
  • Masitinib: Phase III ongoing

    AB Science S.A. (Euronext:AB), Paris, France Product: Masitinib (Masican) (AB1010) Business: Cancer Molecular target: Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) Description: Stem cell factor (…

    Published on 8/24/2015
  • OMS ElectroImmunotherapy: Phase II started

    OncoSec Medical Inc. (NASDAQ:ONCS), San Diego, Calif. Product: OMS ElectroImmunotherapy, ImmunoPulse IL-12, DNA IL-12 Business: Cancer Molecular target: Interleukin-12 (IL-12) Description: DNA plasmid coding for IL-12 …

    Published on 8/24/2015
  • Onapristone ER: Phase I/II amended

    Arno Therapeutics Inc. (OTCQB:ARNI), Flemington, N.J. Invivis Pharmaceuticals Inc., Bridgewater, N.J. Product: Onapristone ER Business: Cancer Molecular target: Progestin receptor Description: Extended-release …

    Published on 8/24/2015
  • SAGE-547: Phase III started

    Sage Therapeutics Inc. (NASDAQ:SAGE), Cambridge, Mass. Product: SAGE-547 Business: Neurology Molecular target: GABA A receptor Description: Positive allosteric modulator (PAM) of GABA A receptor Indication: Treat super-…

    Published on 8/24/2015
  • Seliciclib: Phase II started

    Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J. Product: Seliciclib (R-roscovitine) (CYC202) Business: Other Molecular target: Cyclin dependent kinase (CDK) Description: First-generation inhibitor of…

    Published on 8/24/2015
  • Abacavir acetate: Phase II started

    Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass. Product: Abacavir acetate (Prurisol) (KM-133) Business: Autoimmune Molecular target: NA Description: Small molecule ester of abacavir, a nucleoside analog reverse …

    Published on 8/17/2015
  • Anti-LPA antibody: Phase I start

    Lpath Inc. (NASDAQ:LPTN), San Diego, Calif. Product: Anti-LPA antibody (Lpathomab) Business: Neurology Molecular target: Lysophosphatidic acid (LPA) receptor Description: Human mAb against lysophosphatidic acid (LPA) …

    Published on 8/17/2015
  • ATIR: Completed Phase II enrollment

    Kiadis Pharma N.V. (Euronext:KDS), Amsterdam, the Netherlands Product: ATIR (ATIR101) Business: Transplant Molecular target: Not applicable Description: Cell-based therapy containing mismatched donor lymphocytes …

    Published on 8/17/2015
  • AXS-02: Phase III started

    Axsome Therapeutics Inc., New York, N.Y. Product: AXS-02 Business: Neurology Molecular target: NA Description: Oral osteoclast inhibitor Indication: Treat pain associated with complex regional pain syndrome (CRPS) …

    Published on 8/17/2015
  • BioChaperone insulin combo: Phase Ib started

    Adocia S.A. (Euronext:ADOC; Pink:ADOCY), Lyon, France Product: BioChaperone insulin combo (BioChaperone Combo) Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Combination of long-…

    Published on 8/17/2015
  • BioChaperone insulin combo: Phase Ib started

    Adocia S.A. (Euronext:ADOC; Pink:ADOCY), Lyon, France Product: BioChaperone insulin combo (BioChaperone Combo) Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Combination of long-…

    Published on 8/17/2015
  • CRS-207: Completed Phase Ib enrollment

    Aduro Biotech Inc. (NASDAQ:ADRO), Berkeley, Calif. Product: CRS-207 Business: Cancer Molecular target: NA Description: Live attenuated strain of Listeria monocytogenes that expresses human mesothelin Indication: First-…

    Published on 8/17/2015
  • EBI-005: Phase III started

    Eleven Biotherapeutics Inc. (NASDAQ:EBIO), Cambridge, Mass. Product: EBI-005 Business: Inflammation Molecular target: Interleukin-1 (IL-1) receptor Description: IL-1 receptor antagonist Indication: Treat moderate to …

    Published on 8/17/2015
  • Filgotinib: Completed Phase II enrollment

    Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), Mechelen, Belgium AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Product: Filgotinib (GLPG0634) Business: Autoimmune Molecular target: Janus kinase-1 (JAK-1) Description: Janus …

    Published on 8/17/2015
  • FV-100: Phase III started

    ContraVir Pharmaceuticals Inc. (NASDAQ:CTRV), New York, N.Y. Product: FV-100 Business: Neurology Molecular target: Not available Description: Oral bicyclic nucleoside analog Indication: Prevent post-herpetic neuralgia (…

    Published on 8/17/2015
  • FX006: Phase III complete enrollment

    Flexion Therapeutics Inc. (NASDAQ:FLXN), Burlington, Mass. Product: FX006 Business: Neurology Molecular target: NA Description: Sustained-release intra-articular formulation of triamcinolone acetonide (TCA) Indication: …

    Published on 8/17/2015
  • Masitinib: Phase II ongoing

    AB Science S.A. (Euronext:AB), Paris, France Product: Masitinib (Masican) (AB1010) Business: Cancer Molecular target: Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) Description: Stem cell factor (…

    Published on 8/17/2015
  • Masitinib: Phase II ongoing

    AB Science S.A. (Euronext:AB), Paris, France Product: Masitinib (Masican) (AB1010) Business: Cancer Molecular target: Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) Description: Stem cell factor (…

    Published on 8/17/2015
  • Masitinib: Phase II ongoing

    AB Science S.A. (Euronext:AB), Paris, France Product: Masitinib (Masican) (AB1010) Business: Cancer Molecular target: Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) Description: Stem cell factor (…

    Published on 8/17/2015
  • OMP-131R10: Phase Ia started

    OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), Redwood City, Calif. Product: OMP-131R10 Business: Cancer Molecular target: R-Spondin 3 (RSPO3) Description: mAb targeting R-Spondin 3 (RSPO3) Indication: Treat advanced solid…

    Published on 8/17/2015
  • Staphylococcus lysin: Phase I ongoing

    ContraFect Corp. (NASDAQ:CFRX), Yonkers, N.Y. Product: Staphylococcus lysin (CF-301) Business: Infectious Molecular target: NA Description: Staphylococcal specific lysin protein Indication: Treat Staphylococcus …

    Published on 8/17/2015
  • Tarloxotinib Bromide: Phase II started

    Threshold Pharmaceuticals Inc. (NASDAQ:THLD), South San Francisco, Calif. Product: Tarloxotinib Bromide (TH-4000) (formerly PR-610, PR610, Hypoxin) Business: Cancer Molecular target: Epidermal growth factor receptor (…

    Published on 8/17/2015
  • Abicipar pegol: Phase III started

    Allergan plc (NYSE:AGN), Dublin, Ireland Molecular Partners AG (SIX:MOLN), Schlieren, Switzerland Product: Abicipar pegol (AGN-150998, MP0112) Business: Ophthalmic Molecular target: Vascular endothelial growth factor A…

    Published on 8/10/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993